Where We Are Going: HIV Prevention Science
This plenary will provide a primer for audiences that have limited or minimal knowledge about developing avenues of biomedical HIV prevention science. The strategies that will be highlighted in this plenary are HIV antibody mediated prevention and long acting injectable PrEP, including a focus on where we are currently in research and what we can expect over the next few years. Following the overview of the science and next steps in research, the audience will receive brief updates on major studies in the field for both Networks, including the AMP Study (HIV Vaccine Trials Network (HVTN)-704/HIV Prevention Trials Network (HPTN)-085) - a pioneering study seeking to reduce HIV infection in people through the use of special broadly neutralizing antibodies, and HPTN 083- an innovative study comparing the protective effects of injectable PrEP to oral PrEP. Please join the HPTN and the HVTN for this special plenary.
Saturday, January 20th, 2018
© 2017 · naesm.org.